Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexandre Mebazaa

Showing results (21-30 of 792) with videos related to

Pageof 80
Sort By:
Seminars in Nephrology|February 28, 2012
Cardio-renal syndrome type 2: epidemiology, pathophysiology, and treatmentPreeti Jois, Alexandre Mebazaa
Presse Medicale (Paris, France : 1983)|March 22, 2006
[Severe infections: not a minute to lose for a major national priority]Alexandre Mebazaa, Didier Payen
The American Journal of Cardiology|October 1, 2005
Introduction to acute heart failure syndromesMihai Gheorghiade, Alexandre Mebazaa
Critical Care (London, England)|September 7, 2011
In vivo and in vitro evidence for pleiotropic effects of levosimendan in the intensive care settingMehmet Birhan Yilmaz, Alexandre Mebazaa
Critical Care (London, England)|January 14, 2010
Searching for an ideal hemodynamic marker to predict short-term outcome in cardiogenic shockMehmet Birhan Yilmaz, Alexandre Mebazaa
JACC. Heart Failure|August 8, 2015
Neprilysin: Biotarget and Biomarker in Heart FailureMarie-France Seronde, Alexandre Mebazaa
Biomarkers in Medicine|May 19, 2010
Use of B-type natriuretic peptide in critically ill patientsRomain Pirracchio, Reda Salem, Alexandre Mebazaa
Current Opinion in Critical Care|July 17, 2009
Cardiovascular biomarkers in the ICUMarkus Noveanu, Alexandre Mebazaa, Christian Mueller
Intensive Care Medicine|December 6, 2017
Adjuvant therapy in acute heart failureTahar Chouihed, Alexa Hollinger, Alexandre Mebazaa
European Heart Journal|September 23, 2017
Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARDMattia Arrigo, Alice Blet, Alexandre Mebazaa
Pageof 80

Showing results (21-30 of 792) with videos related to

Sort By:
Pageof 80
Seminars in Nephrology|February 28, 2012
Cardio-renal syndrome type 2: epidemiology, pathophysiology, and treatmentPreeti Jois, Alexandre Mebazaa
Presse Medicale (Paris, France : 1983)|March 22, 2006
[Severe infections: not a minute to lose for a major national priority]Alexandre Mebazaa, Didier Payen
The American Journal of Cardiology|October 1, 2005
Introduction to acute heart failure syndromesMihai Gheorghiade, Alexandre Mebazaa
Critical Care (London, England)|September 7, 2011
In vivo and in vitro evidence for pleiotropic effects of levosimendan in the intensive care settingMehmet Birhan Yilmaz, Alexandre Mebazaa
Critical Care (London, England)|January 14, 2010
Searching for an ideal hemodynamic marker to predict short-term outcome in cardiogenic shockMehmet Birhan Yilmaz, Alexandre Mebazaa
JACC. Heart Failure|August 8, 2015
Neprilysin: Biotarget and Biomarker in Heart FailureMarie-France Seronde, Alexandre Mebazaa
Biomarkers in Medicine|May 19, 2010
Use of B-type natriuretic peptide in critically ill patientsRomain Pirracchio, Reda Salem, Alexandre Mebazaa
Current Opinion in Critical Care|July 17, 2009
Cardiovascular biomarkers in the ICUMarkus Noveanu, Alexandre Mebazaa, Christian Mueller
Intensive Care Medicine|December 6, 2017
Adjuvant therapy in acute heart failureTahar Chouihed, Alexa Hollinger, Alexandre Mebazaa
European Heart Journal|September 23, 2017
Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARDMattia Arrigo, Alice Blet, Alexandre Mebazaa
Pageof 80